Tumor mutational burden (TMB) and response rates to immune checkpoint inhibitors (ICIs) targeting PD-1, CTLA-4, and combination.

被引：4
作者：
Osipov, Arsen
Popovic, Aleksandra
Hopkins, Alexander
Frampton, Garrett M.
Albacker, Lee A.
Azad, Nilofer Saba
Laheru, Daniel A.
Zheng, Lei
Jaffee, Elizabeth M.
Yarchoan, Mark
机构：
[1] Johns Hopkins Univ, Sch Med, Dept Oncol, Balimore, MD USA
[2] Johns Hopkins Univ, Sch Med, Baltimore, MD USA
[3] Johns Hopkins Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA
[4] Fdn Med Inc, Cambridge, MA USA
[5] Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA
[6] Johns Hopkins Univ Hosp, Baltimore, MD USA
[7] Johns Hopkins Univ, Baltimore, MD USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 15期
关键词：
D O I：
10.1200/JCO.2019.37.15_suppl.2578
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2578
引用
收藏
页数：1
相关论文
共 50 条
[1]   Tumor Mutational Burden, Toxicity, and Response of Immune Checkpoint Inhibitors Targeting PD(L)1, CTLA-4, and Combination: A Meta-regression Analysis [J].
Osipov, Arsen ;
Lim, Su Jin ;
Popovic, Aleksandra ;
Azad, Nilofer S. ;
Laheru, Daniel A. ;
Zheng, Lei ;
Jaffee, Elizabeth M. ;
Wang, Hao ;
Yarchoan, Mark .
CLINICAL CANCER RESEARCH, 2020, 26 (18) :4842-4851
[2]   Panel-derived tumor mutational burden (TMB) is associated with the response to the immune checkpoint inhibitors (ICIs) in urothelial cancers [J].
Hsieh, Yi-Lin ;
Yu, Pei-Ning ;
Jan, Yi-Hua ;
Lai, Meng-Shao ;
Wang, Woei-Fuh ;
Zhuo, De-Wei ;
Chen, Shu-Jen ;
Cheng, Jen-Hao ;
Tan, Kien Thiam ;
Su, Yu-Li .
CANCER RESEARCH, 2020, 80 (16)
[3]   Panel-derived tumor mutational burden (TMB) correlates with immune checkpoint inhibitors (ICIs) response in gastrointestinal cancers [J].
Chen, San-chi ;
Tan, Kien-Thiam ;
Chen, Ming-Huang ;
Hung, Yi-Ping ;
Hsieh, Yi-Lin ;
Jan, Yi-Hua ;
Chao, Yee .
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
[4]   Rational Combination of Parvovirus H1 With CTLA-4 and PD-1 Checkpoint Inhibitors Dampens the Tumor Induced Immune Silencing [J].
Goepfert, Katrin ;
Dinsart, Christiane ;
Rommelaere, Jean ;
Foerster, Friedrich ;
Moehler, Markus .
FRONTIERS IN ONCOLOGY, 2019, 9
[5]   Correlation between sex and efficacy of immune checkpoint inhibitors (PD-1 and CTLA-4 inhibitors) [J].
Wu, Yingcheng ;
Ju, Qianqian ;
Jia, Keren ;
Yu, Jingyan ;
Shi, Hui ;
Wu, Huiqun ;
Jiang, Maorong .
INTERNATIONAL JOURNAL OF CANCER, 2018, 143 (01) :45-51
[6]   Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4 [J].
Qin, Shuang ;
Xu, Linping ;
Yi, Ming ;
Yu, Shengnan ;
Wu, Kongming ;
Luo, Suxia .
MOLECULAR CANCER, 2019, 18 (01)
[7]   The future of immune checkpoint cancer therapy after PD-1 and CTLA-4 [J].
Hahn, Andrew W. ;
Gill, David M. ;
Pal, Sumanta K. ;
Agarwal, Neeraj .
IMMUNOTHERAPY, 2017, 9 (08) :681-692
[8]   Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4 [J].
Shuang Qin ;
Linping Xu ;
Ming Yi ;
Shengnan Yu ;
Kongming Wu ;
Suxia Luo .
Molecular Cancer, 18
[9]   Characterization of tumor mutational burden (TMB), PD-L1, and DNA repair genes to assess correlation with immune checkpoint inhibitors (ICIs) response in metastatic renal cell carcinoma (mRCC). [J].
Labriola, Matthew ;
Zhu, Jason ;
Gupta, Rajan ;
McCall, Shannon ;
Jackson, Jennifer ;
White, James R. ;
Weingartner, Elizabeth ;
Kong, Eric ;
Simone, Peter ;
Papp, Eniko ;
Gerding, Kelly ;
Simmons, John ;
George, Daniel J. ;
Zhang, Tian .
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
[10]   Immune checkpoint therapy: From CTLA-4 to PD-1/PD-L1 and beyond [J].
Sharma, Padmanee .
CANCER RESEARCH, 2018, 78 (13)
12345